DCT

1:26-cv-00580

Biogen Ma Inc v. Somerset Therap LLC

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:26-cv-00580, D. Del., 05/20/2026
  • Venue Allegations: Venue is alleged to be proper in the District of Delaware because three of the defendant entities are incorporated in Delaware and maintain registered agents there, thus residing in the district.
  • Core Dispute: Plaintiff alleges that Defendants' submission of an Abbreviated New Drug Application (ANDA) to the FDA for a generic version of the spinal muscular atrophy treatment Spinraza® constitutes an act of infringement of three U.S. patents covering the drug's composition and methods of use.
  • Technical Context: The technology involves an antisense oligonucleotide therapeutic designed to treat spinal muscular atrophy (SMA), a progressive and often fatal neurodegenerative genetic disease, by modulating mRNA splicing.
  • Key Procedural History: This action was triggered by a Paragraph IV certification included in Defendants' ANDA No. 221418, in which Defendants assert that the patents-in-suit are invalid, unenforceable, or will not be infringed by their proposed generic product. The complaint notes that the Somerset defendants have regularly engaged in prior patent litigation in the District of Delaware.

Case Timeline

Date Event
2013-01-09 U.S. Patent No. 9,926,559 Priority Date
2014-09-12 U.S. Patent Nos. 10,436,802 and 12,013,403 Priority Date
2018-03-27 U.S. Patent No. 9,926,559 Issued
2019-10-08 U.S. Patent No. 10,436,802 Issued
2024-06-18 U.S. Patent No. 12,013,403 Issued
2026-04-09 Date of Somerset's Notice Letter
2026-04-10 Biogen receives Somerset's Notice Letter
2026-05-20 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 9,926,559 - "Compositions and methods for modulation of SMN2 splicing in a subject"

  • Patent Identification: U.S. Patent No. 9,926,559, "Compositions and methods for modulation of SMN2 splicing in a subject," issued March 27, 2018 Compl. ¶25

The Invention Explained

  • Problem Addressed: The patent addresses spinal muscular atrophy (SMA), a genetic disorder caused by the loss of the SMN1 gene. A nearly identical gene, SMN2, exists but primarily produces a non-functional protein because of a splicing event that excludes a critical segment, exon 7 '802 Patent, col. 1:49-col. 2:38
  • The Patented Solution: The invention is a synthetic, chemically modified nucleic acid strand known as an antisense oligonucleotide (ASO). This ASO is designed to bind to a specific location on the pre-mRNA transcribed from the SMN2 gene, which redirects the cellular splicing machinery to include exon 7, thereby producing the full-length, functional SMN protein that is otherwise deficient in SMA patients '802 Patent, col. 28:50-col. 29:19
  • Technical Importance: This technology provided a method to leverage the body's existing but underutilized SMN2 gene to produce a functional protein, offering a way to treat the underlying genetic cause of SMA rather than just its symptoms '802 Patent, col. 34:26-35

Key Claims at a Glance

  • The complaint asserts at least independent claim 1 Compl. ¶41
  • The essential elements of Claim 1 are:
    • A method of treating a human subject with SMA.
    • The method comprises administering an antisense oligonucleotide (ASO) of 18 linked nucleosides with the sequence SEQ ID NO: 1.
    • The ASO has specific chemical modifications: each internucleoside linkage is a phosphorothioate, each nucleoside is a 2'-MOE nucleoside, and each cytosine is a 5-methyl cytosine.
    • The ASO is administered into the cerebrospinal fluid by bolus injection into the intrathecal space.
    • The administered dose is one of a select list of specific amounts: 9.6, 10.3, 10.8, 11.3, or 12.0 milligrams Compl. ¶41

U.S. Patent No. 10,436,802 - "Methods for treating Spinal Muscular Atrophy"

  • Patent Identification: U.S. Patent No. 10,436,802, "Methods for treating Spinal Muscular Atrophy," issued October 8, 2019 Compl. ¶28

The Invention Explained

  • Problem Addressed: The patent addresses the need for an effective clinical protocol for administering an SMA therapeutic. Simply having a drug is insufficient; determining the correct dose, timing, and administration route is critical for safety and efficacy, particularly for a neurodegenerative disease '802 Patent, col. 19:56-col. 20:10
  • The Patented Solution: The patent claims a specific method of treatment using a series of "loading doses" of the nusinersen ASO. This regimen involves administering an initial dose, followed by two subsequent doses at specific time intervals (e.g., approximately two and four weeks later) to rapidly achieve a therapeutic concentration of the drug in the central nervous system '802 Patent, col. 49:42-50
  • Technical Importance: Establishing an effective loading dose regimen is a key step in developing a chronic therapy, as it allows for quickly achieving therapeutic drug levels that can then be maintained with subsequent, less frequent dosing.

Key Claims at a Glance

  • The complaint asserts at least independent claim 1 Compl. ¶55
  • The essential elements of Claim 1 are:
    • A method for treating a human subject with SMA symptoms.
    • The method comprises administering by intrathecal injection doses of the same ASO described in the '559 Patent (18-mer, SEQ ID NO: 1, with phosphorothioate, 2'-MOE, and 5-methyl cytosine modifications).
    • The doses comprise a specific loading regimen: (i) a first dose of 12 mg; (ii) a second dose of 12 mg administered 12-18 days after the first dose; and (iii) a third dose of 12 mg administered 25-35 days after the first dose Compl. ¶55

U.S. Patent No. 12,013,403 - "Compositions and methods for detection of SMN protein in a subject and treatment of a subject"

  • Patent Identification: U.S. Patent No. 12,013,403, "Compositions and methods for detection of SMN protein in a subject and treatment of a subject," issued June 18, 2024 Compl. ¶31
  • Technology Synopsis: This patent protects a more extensive method of treating SMA with nusinersen, claiming a six-dose loading and initial maintenance regimen administered over approximately 300 days. The invention provides a long-term treatment protocol that extends beyond the initial loading phase described in the '802 Patent '403 Patent, col. 77:50-col. 78:67
  • Asserted Claims: At least independent claim 1 is asserted Compl. ¶69
  • Accused Features: The complaint alleges that Defendants' proposed generic product, if used as instructed by its anticipated label, will infringe this claimed long-term dosing regimen Compl. ¶¶39, 70-71

III. The Accused Instrumentality

Product Identification

  • The accused instrumentality is the submission by the Somerset Defendants of Abbreviated New Drug Application (ANDA) No. 221418 for approval to market "Somerset's Proposed ANDA Product" Compl. ¶1

Functionality and Market Context

  • The proposed product is a generic version of Biogen's Spinraza®, with nusinersen as the active ingredient, formulated as an intrathecal injection at a concentration of 12 mg/5 mL Compl. ¶1 Compl. ¶37 The complaint alleges that the ANDA filing seeks approval for the same indication as Spinraza®: the treatment of SMA in pediatric and adult patients (Compl. ¶1; Compl. ¶2). The infringement allegation is based on the act of filing the ANDA itself, and on the allegation that the proposed product label will be "substantially identical" to the Spinraza® label, thereby instructing medical professionals to administer the drug in a manner that infringes the asserted patents Compl. ¶39

IV. Analysis of Infringement Allegations

No probative visual evidence provided in complaint.

'559 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
[a] method of treating a human subject having spinal muscular atrophy (SMA), the method comprising administering to the human subject an antisense oligonucleotide... The proposed ANDA product is intended to treat SMA by administering an antisense oligonucleotide, nusinersen. ¶1; ¶37 col. 27:49-53
...consisting of 18 linked nucleosides, wherein the oligonucleotide has a nucleobase sequence consisting of the nucleobase sequence SEQ ID NO: 1... The active ingredient of the proposed product is nusinersen, which is an 18-mer ASO with the nucleobase sequence of SEQ ID NO: 1. ¶37 col. 53:50-54
...wherein each internucleoside linkage of the oligonucleotide is a phosphorothioate linkage, wherein each nucleoside of the oligonucleotide is a 2'-MOE nucleoside, and wherein each cytosine of the oligonucleotide is a 5-methyl cytosine... Nusinersen, the active ingredient, is alleged to have the claimed chemical structure, including the phosphorothioate linkages, 2'-MOE sugars, and 5-methyl cytosine modifications. ¶37; ¶41 col. 25:1-14
...wherein the antisense oligonucleotide is administered into the cerebrospinal fluid by bolus injection into the intrathecal space... The proposed product is an "intrathecal injection," and the proposed label is alleged to instruct administration in a manner that constitutes a bolus injection into the intrathecal space. ¶1; ¶39; ¶41 col. 28:18-24
...at a dose of 9.6, 10.3, 10.8, 11.3, or 12.0 milligrams of the antisense oligonucleotide. The proposed product is a 12 mg/5 mL formulation, and the complaint alleges its proposed use will infringe, suggesting the label will instruct administration of a 12.0 mg dose. ¶1; ¶43 col. 8:5-9

'802 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
[a] method for treating a human subject having one or more symptoms associated with spinal muscular atrophy (SMA), the method comprising administering by intrathecal injection doses of an antisense compound... The proposed product is nusinersen, an ASO for intrathecal injection to treat SMA. Its proposed label is alleged to instruct infringing administration. ¶1; ¶37; ¶39 col. 77:50-65
...wherein the doses comprise: (i) a first dose of 12 mg of the antisense compound; The complaint alleges the proposed label will instruct users to administer the drug in an infringing manner, which would include a first dose of 12 mg. ¶39; ¶57 col. 49:42-50
(ii) a second dose of 12 mg of the antisense compound 12-18 days after administration of the first dose; The proposed label is alleged to be substantially identical to the Spinraza® label, which would instruct a second dose at a time interval falling within the claimed range. ¶39; ¶57 col. 49:42-50
and (iii) a third dose of 12 mg of the antisense compound 25-35 days after administration of the first dose. The proposed label is alleged to be substantially identical to the Spinraza® label, which would instruct a third dose at a time interval falling within the claimed range. ¶39; ¶57 col. 49:42-50
  • Identified Points of Contention:
    • Factual Scope: A primary point of contention will be factual: does the method of administration described in the proposed labeling for Somerset's ANDA product literally meet every limitation of the asserted claims? This will involve a direct comparison of the proposed label's instructions against the specific dosing amounts and schedules recited in the claims of the '559, '802, and '403 patents.
    • Technical Equivalence: Should literal infringement not be found, a potential issue is whether the administration method on the proposed label infringes under the doctrine of equivalents. This would raise the question of whether any differences between the proposed use and the claimed methods are insubstantial.

V. Key Claim Terms for Construction

  • The Term: "bolus injection" ('559 Patent, Claim 1)

    • Context and Importance: This term defines the specific manner of intrathecal administration. The infringement analysis will depend on whether the administration procedure described in the defendants' proposed label qualifies as a "bolus injection" as opposed to another method, such as a slow infusion. Practitioners may focus on this term because the distinction between a rapid injection and a slow infusion could be a basis for a non-infringement argument.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: The patent specification does not appear to provide an explicit definition that limits the term's scope, which may support an argument that the term should be given its plain and ordinary meaning as understood by a person of ordinary skill in the art at the time of the invention.
      • Evidence for a Narrower Interpretation: The specification of the related '802 Patent contrasts "bolus injection" with "infusion with a delivery pump" '802 Patent, col. 3:25-26 A party could argue this distinction implies that a "bolus injection" must be a rapid, single push, as opposed to a more controlled, slower administration that might be characterized as an infusion.

  • The Term: "treating" ('802 Patent, Claim 1)

    • Context and Importance: As this is a method of treatment claim, the meaning of "treating" is fundamental. In the context of an ANDA case under 35 U.S.C. § 271(e)(2), the act of infringement is submitting the ANDA for a use claimed in a patent. The dispute will center on whether seeking approval to market a drug with a label that instructs for the claimed method of "treating" SMA constitutes infringement.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: The '802 Patent specification describes "treatment" as "the application of one or more specific procedures used for the cure or amelioration of a disease," and "amelioration" as "a lessening of severity of at least one indicator of a condition or disease" '802 Patent, col. 20:56-61 This language could support a broad definition covering any level of symptom improvement.
      • Evidence for a Narrower Interpretation: A defendant might argue that "treating" implies achieving a specific, clinically meaningful outcome described in the patent's examples or clinical trial data, such as a particular score on the Hammersmith Functional Motor Scale-Expanded (HFMSE) '802 Patent, col. 51:45-52:2 This could support an argument that merely providing the drug does not equate to successful "treating" unless a certain efficacy threshold is met, though this is a less common construction for this term.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges active inducement of infringement for all three asserted patents. The basis for this allegation is that the Somerset Defendants' proposed product label will intentionally encourage and instruct healthcare professionals to administer the generic product in a manner that directly infringes the claims Compl. ¶¶50 Compl. ¶64 Compl. ¶78 The complaint also alleges contributory infringement, stating the product is especially made for the patented methods and is not suitable for substantial noninfringing use Compl. ¶¶51 Compl. ¶65 Compl. ¶79
  • Willful Infringement: The complaint does not contain a separate count for willful infringement but lays the factual groundwork for such a claim. It alleges that the Somerset Defendants had pre-suit knowledge of the Asserted Patents because the patents are listed in the FDA's Orange Book for Spinraza® and were explicitly referenced in the notice letter sent to Biogen Compl. ¶¶49 Compl. ¶63 Compl. ¶77

VII. Analyst's Conclusion: Key Questions for the Case

  1. A Core Factual Question of Infringement: Will the instructions for use on the defendants' proposed drug label, once finalized, recommend a dosage and administration schedule that falls within the specific ranges and timings recited in Biogen's asserted method claims? The outcome of the infringement analysis will depend heavily on this comparison between the label and the claim language.

  2. A Central Legal Question of Validity: Given that this is an ANDA litigation initiated by a Paragraph IV certification, a key issue for the court will be the validity of the asserted claims. The case will likely involve significant disputes over whether the claimed ASO composition and, in particular, the specific dosing regimens were obvious to a person of ordinary skill in the art at the time of the invention, based on prior art knowledge of ASO therapeutics and clinical trial design.

  3. The Question of Injunctive Relief: As this suit was filed under the Hatch-Waxman Act, a critical question is whether Biogen can secure an injunction. This will turn on the court's findings on infringement and validity and will determine whether the FDA can approve Somerset's ANDA before the expiration of the asserted patents.

Loading Complaint